ZYIL1, developed by Zydus Lifesciences, inhibits the NLRP3 pathway by blocking ASC oligomerization and is in a Phase 2 trial for ALS (NCT05981040) [46]. Here, NLRP3 is linked to amyotrophic lateral sclerosis.